Developing COVID-19 Vaccines in Record Time

NAIIS – 5/12/2020

• Welcome – L.J Tan (IAC)
• Introductions – Phyllis Arthur (BIO)
• Presentations
  • Laurent M. Humeau, PhD, Chief Science Officer and EVP of Research, Engineering and Clinical Developments, Inovio
  • Marcus Divanghi, MD, MPH, Head of Clinical Development, Janssen Vaccines
  • Mike Wikswo, MD, Consultant, Vaccines and Infectious Diseases, Moderna
  • Greg Glenn, MD, President, Research and Development, Novavax
  • Philip Dormitzer, MD, PhD, VP and Chief Scientific Officer, Viral Vaccines, Pfizer
  • Clement Lewin, MBA, Associate Vice President, Head BARDA Office & NV Stakeholder Engagement, Sanofi Pasteur

COVID-19 US Vaccine Introduction Overview

Initial Response

Distribution (HHS assumption)
• Like H1N1, HHS will purchase doses and direct distribution from manufacturer to PODS (Point of Delivery System)
• State of Florida tapped
•uslim capacity with capacity and uptake
• Vaccine shortage very high to start time likely wane over time

Prioritization

Assumptions: Directed by CDC/ACIP; HHS/NVAC; Initially indicated for States:
• Epidemiology
• Safety
• Efficacy
• Duration of Immunity – natural & conferred
• HEOR
• Consumer interest

Transition to Routine?

Routine immunization based on ACIP guidance developed from Evidence to Recommendation (E2R) process using:
• Epidemiology
• Safety
• Duration of Immunity – natural & conferred
• HEOR
• Consumer interest

100 Vaccines
135 Antiretroviral
142 Clinical Compounds
288 Preclinical Compounds
195 Treatments

bio.org/covidpipelinetracker